JP Morgan Knock-Out ARRD/ DE000JA22366 /
31/05/2024 11:51:48 | Diferencia-0.04 | Bid13:44:46 | Ask13:44:46 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
2.07EUR | -1.90% | 2.07 Volumen de oferta: 200,000 |
2.08 Tamaño/ Volumen/ Formato de Ask: 200,000 |
ARCELORMITTAL S.A. N... | 44.7637 EUR | 31/12/2078 | Put |
GlobeNewswire
14:05
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14:00
Haoxi Health Technology Limited Reports Unaudited Financial Results for The Six Months Ended Decembe...
GlobeNewswire
14:00
Generation Lab Introduces First Platform that Measures Aging & Treatment Efficacy to Help Extend the...
GlobeNewswire
14:00
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 ...
GlobeNewswire
14:00
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 i...
GlobeNewswire
14:00
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
GlobeNewswire
14:00
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
14:00
PodcastOne (Nasdaq: PODC) Appoints Wall Street Veteran Jon Merriman to Its Board of Directors
GlobeNewswire
14:00
ABM Named Among Barron’s 100 Most Sustainable Companies for Second Consecutive Year
GlobeNewswire
14:00
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatm...
GlobeNewswire
14:00
SOND INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sonder Holdings Inc. Investors...
GlobeNewswire
13:30
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clon...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página